參考文獻(xiàn)：

[1]YANG W,LU J,WENG J, et al. Prevalence of diabetes among men and women in China[J].NEng J Med,2010,362:1090-1101.

[2] Horn JR, Gumpper KF, Hardy JC, et al.Clinical decision support for drug-drug interactions: Improvement needed [J].Am J Health Syst Pharm, 2013, 70(10): 905-909

[3]菅凌燕,何曉靜,李曉冰. 與α-糖苷酶抑制劑治療相關(guān)的藥物相互作用[J]. 藥品評價,2015,12(17):21-24.

[4] May M,Schindler C.Clinically and pharmacologically relevant interactions of antidiabeticdrugs.Ther Adv Endocrinol Metab. 2016 ,7(2):69-83.

[5]Irving SA1, Vadiveloo T, Leese GP. Drugs thatinteract with levothyroxine: an observational study from the ThyroidEpidemiology, Audit and Research Study (TEARS).Clin Endocrinol (Oxf). 2015,82(1):136-141

[6]Rizzoli R1, Reginster JY, Boonen S, etal.Adverse reactions and drug-drug interactions in the management of women withpostmenopausal osteoporosis. Calcif Tissue Int. 2011,89(2):91-104.

[7]Kusumoto M, Ueno K, Fujimura Y, et al. Lack ofkinetic interaction between digoxin and voglibose.Eur J Clin Pharmacol. 1999 ,55(1):79-80.

[8]Tahboub R, Arafah BM. Sex steroids and thethyroid .Best Pract Res Clin Endocrinol Metab. 2009 ,23(6):769-780.

[9]李中東,施孝金,王宏圖.左甲狀腺素鈉的藥物相互作用及機(jī)制初探.藥學(xué)服務(wù)與研究 2003, 3(1):59-61

[10]Yang R, Luo Z, Liu Y1, Sun M.DrugInteractions with Angiotensin Receptor Blockers: Role of Human CytochromesP450.Curr Drug Metab. 2016;17(7):681-691.

[11]Tornio A, Niemi M, Neuvonen PJ, Druginteractions with oral antidiabetic agents: pharmacokinetic mechanisms andclinical implications.Trends Pharmacol Sci. 2012 ,33(6):312-322.

[12]Scheen A J. Dipeptidylpeptidase-4 inhibitors(gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010,49(9):573-588

[13]Hurren KM1, Pinelli NR. Drug-druginteractions with glucagon-like peptide-1 receptor agonists. Ann Pharmacother.2012,46(5):710-717.

[14]母義明. 2型糖尿病治療中的藥物相互作用[J]. 藥品評價,2015,12(17):8-14

[15] Zhou YT, YuLS, ZengS, et al.Pharmacokinetic drug-drug interactions between 1.4-dihydropyridine calciumchannel blockers and statins: factors determining interaction strength andrelevant clinical risk management. Ther Clin Risk Manag. 2014;10:17-26. 

[16]Wiggins BS, Saseen JJ, Page RL2nd,Recommendations for Management of Clinically Significant Drug-DrugInteractions With Statins and Select Agents Used in Patients WithCardiovascular Disease: A Scientific Statement From the American Heart Association.Circulation.2016, 22;134(21):468-495.

[17]徐海燕,劉冬,王文剛,孔令提. 他汀類藥物與常見心血管藥物相互作用的研究進(jìn)展[J]. 中國藥房,2016,27(11):1582-1584.

[18]Matoulková P1, Pávek P, Maly J, et al. Cytochrome P450 enzymeregulation by glucocorticoids and consequences in terms of drug interaction.Expert Opin Drug Metab Toxicol. 2014 ,10(3):425-35.

[19]Stage TB, Br?sen K, Christensen MM, et al.A Comprehensive Review of Drug-Drug Interactions withMetformin. Clin Pharmacokinet (2015) 54:811–824

[20]Koepsell H. Role of organic cation transportersin drug-drug interaction. Expert Opin Drug Metab Toxicol. 2015;11(10):1619-1633.

[21]Johansson S, Read J, Oliver S.Pharmacokineticevaluations of the co-administrations of vandetanib and metformin, digoxin,midazolam, omeprazole or ranitidine.Clin Pharmacokinet. 2014 ,53(9):837-47.

[22]Rehman SU, Choi MS, Choe K, et al. Interactionsbetween herbs and antidiabetics: an overview of the mechanisms, evidence,importance, and management. Arch Pharm Res. 2015 ,38(7):1281-98.